(Q44402921)

2 December 2017

title

Antifungal susceptibility testing of micafungin against Candida glabrata isolates (English)

1 reference

2 December 2017

0 references

4

Thomas F Patterson

1 reference

2 December 2017

William R. Kirkpatrick

series ordinal

3

object named as

William R Kirkpatrick

1 reference

2 December 2017

Erica R Oliveira

1

1 reference

2 December 2017

Annette Fothergill

series ordinal

2

1 reference

2 December 2017

Spencer W Redding

series ordinal

5

1 reference

2 December 2017

publication date

1 April 2008

1 reference

Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics

2 December 2017

number of pages

3

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

2 December 2017

volume

105

1 reference

2 December 2017

issue

4

1 reference

2 December 2017

page(s)

457-459

1 reference

Global distribution and outcomes for Candida species causing invasive candidiasis: results from an international randomized double-blind study of caspofungin versus amphotericin B for the treatment of invasive candidiasis

2 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2007.12.003

Attributable mortality of nosocomial candidemia, revisited

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2007.12.003

Guidelines for treatment of candidiasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2007.12.003

Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin America, 1997-1998.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2007.12.003

Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2007.12.003

The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2007.12.003

Changing patterns and trends in systemic fungal infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2007.12.003

Echinocandin antifungal drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2007.12.003

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2007.12.003

Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2007.12.003

In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2007.12.003

In vitro antifungal activity of FK463, a new water-soluble echinocandin-like lipopeptide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2007.12.003

In-vitro activity of voriconazole (UK-109,496), LY303366 and other antifungal agents against oral Candida spp. isolates from HIV-infected patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2007.12.003

In vitro activity of micafungin (FK-463) against Candida spp.: microdilution, time-kill, and postantifungal-effect studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2007.12.003

In vitro activity of three new triazoles and one echinocandin against Candida bloodstream isolates from cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2007.12.003

10.1016/J.TRIPLEO.2007.12.003

7 January 2021

Identifiers

DOI

1 reference

2 December 2017

1 reference